Pure Global AI
NCT06287476Not yet recruiting

Alveolar-capillary Reserve After Exercise in Chronic Obstructive Pulmonary Disease (COPD) (COP-DTPA)

Alveolar-capillary Reserve After Exercise in COPD
Rigshospitalet, DenmarkClinicalTrials.govother
Verified
Study focus
Disease/Condition
Chronic Obstructive Pulmonary Disease
Drug/Device/Intervention
Acute exercise bout on visit 2 and 3
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Rigshospitalet, Denmark
Location
Copenhagen, Denmark
Timeline & enrollment
Phase
N/A
Start date
Mar 15, 2024
End date
Mar 15, 2025
Enrollment
32 participants
Primary outcome

Rest-to-exercise pulmonary DTPA clearance change after exercise in COPD vs. controls

Summary

It is unknown whether individuals with COPD exhibit abnormal alveolar-capillary breaching
 during exercise, and whether this contributes to exertional dyspnoea. The aim of this study
 is to investigate whether individuals with COPD exhibit an abnormal increase in
 alveolar-capillary breaching during exertion, as indicated by an increase alveolar-capillary
 permeability with a concomitantly exacerbated increase in lung tissue mass.

ICD-10 classifications
Other chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease, unspecifiedOther specified chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease with acute exacerbation, unspecifiedChronic obstructive pulmonary disease with acute lower respiratory infection
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06287476
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06287476 through Pure Global AI's free database. This phase not specified trial is sponsored by Rigshospitalet, Denmark and is currently Not yet recruiting. The study focuses on Chronic Obstructive Pulmonary Disease. Target enrollment is 32 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.